Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 125, Issue 1, Pages 212-221Publisher
WILEY
DOI: 10.1002/ijc.24351
Keywords
ADCC; ULBP; NKG2D; lymphoma; rituximab
Categories
Funding
- Ministry of Education, Culture, Science, Sports, and Technology. Japan [19390266, 80405183, 17016065, 16062101]
- Ministry of Health, Labor, and Welfare, Japan [17S-1, 17-16, 19-8]
- Grants-in-Aid for Scientific Research [17016065, 19390266, 16062101] Funding Source: KAKEN
Ask authors/readers for more resources
Anti body-dependent cellular cytotoxicity (ADCC) is a major antitumor mechanism of action of therapeutic monoclonal antibodies (mAbs). The aim of this study was to identify tumor-associated factors which determine susceptibility to rituximab-induced ADCC. Thirty different CD20+ non-Hodgkin lymphoma cell lines were phenotyped for characteristics such as level of expression of NKG2D ligands, and the influence thereof on susceptibility to rituximab-induced ADCC was established. The present study demonstrated that tumor cell susceptibility to rituximab-induced ADCC was determined by 3 major tumor-associated factors: (i) the amount of the target molecule, CD20; (ii) the amount of the ligands for inhibitory killer Ig-like receptors, major histocompatibility complex class 1; and (iii) the amounts of some of the NKG2D ligands, especially UL16-binding protein (ULBP) 1-3. The importance of the ULBPs was confirmed using antibody blockade. In conclusion., this is the first report to show the importance for rituximab-induced ADCC of ULBPs expressed on tumor cells. The ULBPs could be valuable diagnostic biological markers and significant targets for immunotherapy to improve efficacy not only of rituximab but also of other therapeutic mAbs. (C) 2009 UICC
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available